RC48+Carboplatin+Bevacizumab Clinical Trials

2 actively recruiting trials

Pipeline

Phase 2: 2

Top Sponsors

Peking University Cancer Hospital & Institute1
Jiangsu Cancer Institute & Hospital1

Indications

Cancer2
Ovarian Cancer Metastatic Recurrent1
Ovarian Cancer Metastatic1
Primary Peritoneal Carcinoma1
Fallopian Tube Carcinoma1

Other2 trials

Disitamab Vedotin Combined With Platinum and Bevacizumab as First-Line and Maintenance Therapy for HER2-Expressing, HRD-Negative High-Risk Ovarian Cancer: A Multicenter, Non-Randomized, Single-Arm Phase II Clinical Study

Phase 2

RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.